Literature DB >> 11697819

Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors.

M Blank1, G Lavie, M Mandel, Y Keisari.   

Abstract

The tumoricidal properties of photodynamic therapy (PDT) with hypericin (HY) were evaluated in a highly metastatic adenocarcinoma (DA3Hi) and anaplastic squamous cell carcinoma (SQ2) tumors in vivo. Photosensitization of the tumor site with hypericin (HY-PDT) reduced primary tumor development and significantly prolonged the survival of tumor-bearing (TB) mice. Of these two tumors the squamous cell carcinoma emerged as more sensitive to HY-PDT compared with DA3Hi adenocarcinoma both in vitro and in vivo. HY-PDT caused extensive tumor necrosis that was followed by local, intratumoral, and systemic inflammatory reactions. Analyses of cytokine mRNA profiles reveal increases in mRNA levels of expression confined to inflammation-related cytokines both within the tumor and also systemically (measured in spleens). However, there was no evidence for any HY-PDT-induced antitumoral immune reactions. Our results suggest that PDT with hypericin can be considered as a supplementary treatment in the management of some invasive and metastatic cancers such as squamous carcinoma and similar tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11697819     DOI: 10.3727/096504001108747864

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  7 in total

1.  Folic acid conjugated ferritins as photosensitizer carriers for photodynamic therapy.

Authors:  Zipeng Zhen; Wei Tang; Weizhong Zhang; Jin Xie
Journal:  Nanoscale       Date:  2015-06-21       Impact factor: 7.790

2.  The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.

Authors:  Alan Belicha-Villanueva; Jonah Riddell; Naveen Bangia; Sandra O Gollnick
Journal:  Lasers Surg Med       Date:  2012-01-03       Impact factor: 4.025

Review 3.  Enhancement of anti-tumor immunity by photodynamic therapy.

Authors:  Sandra O Gollnick; Craig M Brackett
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

4.  Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease.

Authors:  Madeeha Shams; Barbara Owczarczak; Patricia Manderscheid-Kern; David A Bellnier; Sandra O Gollnick
Journal:  Cancer Immunol Immunother       Date:  2014-11-11       Impact factor: 6.968

5.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells.

Authors:  E Kabingu; L Vaughan; B Owczarczak; K D Ramsey; S O Gollnick
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

Review 7.  Animal models for photodynamic therapy (PDT).

Authors:  Zenildo Santos Silva; Sandra Kalil Bussadori; Kristianne Porta Santos Fernandes; Ying-Ying Huang; Michael R Hamblin
Journal:  Biosci Rep       Date:  2015-09-28       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.